Abstract
Cdc25A, a dual specificity protein phosphatase, is well-recognized as a critical regulator for cell cycle progression. We recently found that it also regulates mitogen-activated protein kinase (MAPK) signal transduction pathway. Inhibition of Cdc25A activity by a K vitamin analog Compound 5 (Cpd 5) can induce a strong and prolonged activation of epidermal growth factor receptor (EGFR)- MAPK pathway, which leads to suppression of transcription factors CREB and c-Myc, resulting in decreased expression of Cdc25A and cyclin D1 levels. Our investigations suggest that Cdc25A plays a central role in regulating and linking cell cycle progression and MAPK signal transduction pathways. Several other recently synthesized K vitamin analogs also affect this pathway, including the non-quinone PM20 and fluoro-Cpd 5. Thus, searching for new and efficient small molecules to inhibit Cdc25A activity may provide new means to control cancers of the liver and other sites.
Keywords: Hepatoma, Cdc25A, compound 5, protein phosphatases, cell growth inhibition, MAP kinase, cell cycle, tyrosine phosphorylation
Anti-Cancer Agents in Medicinal Chemistry
Title: Cdc25A Protein Phosphatase: A Therapeutic Target for Liver Cancer Therapies
Volume: 8 Issue: 8
Author(s): Z. Wang, S. Kar and B. I. Carr
Affiliation:
Keywords: Hepatoma, Cdc25A, compound 5, protein phosphatases, cell growth inhibition, MAP kinase, cell cycle, tyrosine phosphorylation
Abstract: Cdc25A, a dual specificity protein phosphatase, is well-recognized as a critical regulator for cell cycle progression. We recently found that it also regulates mitogen-activated protein kinase (MAPK) signal transduction pathway. Inhibition of Cdc25A activity by a K vitamin analog Compound 5 (Cpd 5) can induce a strong and prolonged activation of epidermal growth factor receptor (EGFR)- MAPK pathway, which leads to suppression of transcription factors CREB and c-Myc, resulting in decreased expression of Cdc25A and cyclin D1 levels. Our investigations suggest that Cdc25A plays a central role in regulating and linking cell cycle progression and MAPK signal transduction pathways. Several other recently synthesized K vitamin analogs also affect this pathway, including the non-quinone PM20 and fluoro-Cpd 5. Thus, searching for new and efficient small molecules to inhibit Cdc25A activity may provide new means to control cancers of the liver and other sites.
Export Options
About this article
Cite this article as:
Wang Z., Kar S. and Carr I. B., Cdc25A Protein Phosphatase: A Therapeutic Target for Liver Cancer Therapies, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (8) . https://dx.doi.org/10.2174/187152008786847675
DOI https://dx.doi.org/10.2174/187152008786847675 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design Recent Patents Concerning Diagnostic and Therapeutic Applications of Aberrantly Methylated Sequences in Pancreatic Cancer
Recent Patents on DNA & Gene Sequences Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular)
Current Medicinal Chemistry The Digenea Parasite Opisthorchis felineus: A Target for the Discovery and Development of Novel Drugs
Infectious Disorders - Drug Targets Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Knockdown of Insulin-Like Growth Factor I Receptor Inhibits the Growth and Enhances Chemo-Sensitivity of Liver Cancer Cells
Current Cancer Drug Targets Immunomodulatory Activity of Astragalus, Ginseng and Echinacea: From Keith Block and Mark Mead to Today, Have We Moved On?
Current Immunology Reviews (Discontinued) Signal Transduction Mechanisms of Alcoholic Fatty Liver Disease: Emer ging Role of Lipin-1
Current Molecular Pharmacology Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia
Current Cancer Drug Targets Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Editorial: Signalling Pathways in Virus-caused Cancers
Current Cancer Drug Targets Nucleoprotein-Derived and Unbound Ribonucleosides: Bioactivity and Potential Applications
Current Pharmaceutical Design Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Exploring Confluence-Related Signalling to Modulate the Expression of Oct4 – A Role in Facilitating Mouse Somatic Cell Reprogramming?
Current Stem Cell Research & Therapy Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery